5月28日,复星医药(600196/02196)发布公告,控股子公司药友制药与智翔金泰(688443)签订了《许可协议》。根据协议,药友制药获智翔金泰授予许可产品(即以纬利妥米单克隆抗体(GR1803)为唯一活性成分及/或约定的同时靶向 BCMA 和 CD3 的双特异性抗体药品)在中国及港澳台地区的临床开发和商业化的独占权利,同时拥有生产工艺研究和生产的排他权利。药友制药将作为该产品在许可区域的...
Source Link5月28日,复星医药(600196/02196)发布公告,控股子公司药友制药与智翔金泰(688443)签订了《许可协议》。根据协议,药友制药获智翔金泰授予许可产品(即以纬利妥米单克隆抗体(GR1803)为唯一活性成分及/或约定的同时靶向 BCMA 和 CD3 的双特异性抗体药品)在中国及港澳台地区的临床开发和商业化的独占权利,同时拥有生产工艺研究和生产的排他权利。药友制药将作为该产品在许可区域的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.